The ReAIX platforms
From billions of possible conditions to the few worth testing. ReAIX combines AI, physics-based simulation and annealing-based optimization to find better conditions with fewer experiments.
Selected by leading programs
Program member
AppWorks #33
Inaugural cohort
4th cohortThe problem
Finding the right conditions means searching millions of combinations, and the answer found in the lab often stops working at scale. Every experiment costs time, material and API.
106+
Solvent, catalyst, ligand, temperature and dosing combine into millions of options. Experiments alone can only sample a small fraction of them.
mg → kg
Mixing, heat transfer and mass transfer change as the vessel grows. The optimum found at bench scale shifts once the process reaches the pilot plant.
kg / run
Every pilot or plant run consumes kilograms of material and API. Teams cannot afford to search for new parameters at scale, so they rely on rules of thumb.
f(x) = ?
DoE campaigns often run many experiments just to fit a kinetic model whose equation was chosen in advance. The fitted model explains the data it was built on, and the next process starts the cycle again.
ReAIX changes the order. It learns the physicochemical properties of each modality, from small molecules to biologics, along with your process data and how process scientists reason, so its answers carry across processes. For scale-up, it is trained on first-principles simulations, so you get predictions without rerunning them. See our method →
ReAIX
From how the drug substance is made to how it becomes a stable drug product. ReAIX Chem and ReAIX Bio optimize drug substance processes for small molecules and biologics; ReAIX Formulation develops the drug product.
Drug substance · Small molecules
Optimizes reaction conditions for API synthesis and ranks the next experiments to run.
Drug substance · Biologics
From antibody developability and sequence to upstream process development and scale-up, with AI models that replace slow simulations.
Drug product · Formulation
Predicts API–excipient compatibility and formulation stability before lab work begins. Currently focused on small-molecule drug products.
Partners
Latest from Vernus AI
Founder & CEO Jimmy Lin will give a keynote at the opening ceremony of the Seongnam Bio-Healthcare International Convention on October 29, on turning AI drug discovery into global biohealth business.
Read the story →
Selected from 2,000+ applications worldwide as one of three Taiwanese startups, Vernus AI will join Google DeepMind and Google Cloud experts in Mountain View.
Read the story →
Meet the team at Fiera Milano, October 6–8, at Booth 8F61 (AI & Tech Zone) and Booth 8F2 (Taiwan Pharma Pavilion), and see ReAIX Chem, Bio and Formulation in action.
Read the story →Get started
Start a trial of ReAIX Chem, ReAIX Bio or ReAIX Formulation. We activate your account and send you complete instructions to get your first results.